Curis, Inc.

Curis, Inc. is a biotech company developing cancer treatments. Its pipeline includes Emavusertib, Fimepinostat, CA-170, and CA-327, which are in various stages of development. The company has a collaboration agreement with Genentech and Roche for Erivedge, an advanced basal cell carcinoma treatment. It also has an agreement with Aurigene Discovery Technologies Limited for immuno-oncology and precision oncology compounds. Curis licensed four programs under the Aurigene collaboration, including emavusertib. The company was incorporated in 2000 and is headquartered in Massachusetts.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

1.2 USD

Potential

-100%

Strengths

The company has high returns. ROIC (100.00%) is higher than the sector mean (6.02%).
EV/EBITDA (0.14) is lower than the sector mean (85.60).
EV/EBIT (0.13) is lower than the sector mean.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
Analysts expect revenues to decline in the coming year.
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	0.2
Price/Free Cash Flow'	100.0
ROIC	100.0%
Net Debt/EBITDA	0.4

Curis, Inc.

Overview

Strengths

Weaknesses

Key Financial Data